Baird analyst Michael Ulz lowered the price target on Proteon Therapeutics (NASDAQ: PRTO) to $1.00 (from $3.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

JMP Securities Downgrades Proteon Therapeutics (PRTO) to Market PerformMarch 28, 2019 10:58 AM Maxim Group Downgrades Proteon Therapeutics (PRTO) to HoldMarch 28, 2019 10:42 AM Pre-Open Stock Movers 03/28: (QTNA) (LULU) (PVH) Higher; (PRTO) (WBC) (NLSN) Lower (more...)March 28, 2019 9:27 AM Proteon Therapeutics (PRTO) to Resume Trading at 8:30 am ETMarch 28, 2019 8:08 AM Form 8-K PROTEON THERAPEUTICS For: Mar 28March 28, 2019 8:03 AM Proteon Therapeutics (PRTO) Phase 3 PATENCY-2 Clinical Trial of Vonapanitase in Radiocephalic Arteriovenous Fistulas Didn't Meet Co-Primary EndpointsMarch 28, 2019 8:02 AM Proteon Therapeutics Announces Top-Line Results From Phase 3 PATENCY-2 Clinical Trial of Vonapanitase in Radiocephalic Arteriovenous FistulasMarch 28, 2019 8:00 AM